Market Place
Sourcing Support
Oculis to Present at the Stifel 2024 Healthcare Conference
13 Nov 2024 //
GLOBENEWSWIRE
Oculis Reports Q3 2024 Financial Results & Company Updates
07 Nov 2024 //
GLOBENEWSWIRE
Oculis Accelerates Enrollment In DIAMOND Phase 3 Trials Of OCS-01
21 Oct 2024 //
GLOBENEWSWIRE
Oculis’ Diamond Phase 3 Program To Be Presented At Innovate Retina
15 Oct 2024 //
GLOBENEWSWIRE
Oculis Appoints Daniel S. Char as Chief Legal Officer
02 Oct 2024 //
GLOBENEWSWIRE
Oculis And EURETINA Announce Ramin Tadayoni Award Winner
19 Sep 2024 //
GLOBENEWSWIRE
Oculis to Present at Upcoming September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Oculis Closes Phase III Eye Drop Trial Due to Third-Party Administrative Error
28 Aug 2024 //
BIOSPACE
Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
27 Aug 2024 //
GLOBENEWSWIRE
Oculis Publishes Consolidated Q2 Financial Statements and MD&A
27 Aug 2024 //
GLOBENEWSWIRE
Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer
15 Aug 2024 //
GLOBENEWSWIRE
Oculis Appoints Dr. Sharon Klier as Chief Development Officer
15 Aug 2024 //
CONTRACT PHARMA
Oculis To Participate In H.C. Wainwright Ophthalmology Conference
30 Jul 2024 //
GLOBENEWSWIRE
Oculis and EURETINA Announces the Ramin Tadayoni Award
27 Jun 2024 //
GLOBENEWSWIRE
Oculis Reports Positive Licaminlimab Dry Eye Phase 2b Trial Data
10 Jun 2024 //
GLOBENEWSWIRE
Oculis sees promise in dry eye disease subgroup, plans phase 3
10 Jun 2024 //
FIERCE BIOTECH
Oculis: Managerial Transactions Notifications Published
04 Jun 2024 //
GLOBENEWSWIRE
Oculis Announces Board And Advisory Board Appointments After 2024 AGM
30 May 2024 //
GLOBENEWSWIRE
Oculis updates share capital for its existing at-the-market offering program
17 May 2024 //
GLOBENEWSWIRE
Oculis OCS-05 Acute Optic Neuritis Phase 2 Enrollment Complete
08 May 2024 //
GLOBENEWSWIRE
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08 May 2024 //
GLOBENEWSWIRE
Oculis Publishes Invitation to the Annual General Meeting
06 May 2024 //
GLOBENEWSWIRE
Oculis to Present at Bank of America Global Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Oculis Publishes Invitation to the Annual General Meeting
29 Apr 2024 //
GLOBENEWSWIRE
Oculis Registered Direct Offering Close, Nasdaq Iceland Trading
22 Apr 2024 //
GLOBENEWSWIRE
Oculis $59M Offering, Nasdaq Iceland Listing
11 Apr 2024 //
GLOBENEWSWIRE
Oculis Appoints Snehal Shah as President of R&D
10 Apr 2024 //
GLOBENEWSWIRE
Oculis to Participate at Upcoming April Investor Conferences
04 Apr 2024 //
GLOBENEWSWIRE
Oculis Reports Q4 and Full Year 2023 Financial Results and Update
18 Mar 2024 //
GLOBENEWSWIRE
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials
28 Feb 2024 //
GLOBENEWSWIRE
Oculis to Present at Upcoming February Investor Conferences
29 Jan 2024 //
GLOBENEWSWIRE
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22 Jan 2024 //
GLOBENEWSWIRE
Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01
20 Dec 2023 //
GLOBENEWSWIRE
Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01
18 Dec 2023 //
GLOBENEWSWIRE
Oculis Announces First Patient First Visit in Ph 2b RELIEF Trial of Licaminlimab
07 Dec 2023 //
GLOBENEWSWIRE
Oculis Reports Q3 2023 Financial Results and Provides Company Update
15 Nov 2023 //
GLOBENEWSWIRE
Oculis to Present at Upcoming November Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Oculis to Present Abstract at American Academy of Ophthalmology Annual Meeting
01 Nov 2023 //
GLOBENEWSWIRE
Positive Phase 3 Trial Results of OCS-01 in Diabetic Macular Edema Presented
10 Oct 2023 //
GLOBENEWSWIRE
Oculis to Present Abstract on Positive Phase 3 Stage 1 DIAMOND Trial Results
05 Oct 2023 //
GLOBENEWSWIRE
Oculis Expands its Executive Leadership Team
11 Sep 2023 //
GLOBENEWSWIRE
OCS-01, Investigational Eye Drop for Back of the Eye, Met Primary Endpoints
08 Aug 2023 //
GLOBENEWSWIRE
Oculis eye drop secures another late-stage win
08 Aug 2023 //
ENDPTS
First Patient Enrolled in LEOPARD, with OCS-01 Eye Drops
02 Aug 2023 //
GLOBENEWSWIRE
Oculis Announces to Present at Upcoming August Investor Conferences
26 Jul 2023 //
GLOBENEWSWIRE
Oculis to Present at OIS Retina Innovation Summit
19 Jul 2023 //
GLOBENEWSWIRE
Oculis to Host an R&D Day to Showcase Programs Targeting Diabetic Macular Edema
26 Jun 2023 //
GLOBENEWSWIRE
Oculis Announces Partial Exercise of Underwriters Option to Purchase Shares
13 Jun 2023 //
GLOBENEWSWIRE
Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association
12 Jun 2023 //
GLOBENEWSWIRE
Oculis to Participate in Jefferies Healthcare Conference
01 Jun 2023 //
GLOBENEWSWIRE
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
31 May 2023 //
GLOBENEWSWIRE
Oculis to Participate and Present at Upcoming EuDES Meeting
24 May 2023 //
GLOBENEWSWIRE
Oculis` eye drug meets main goal in study
22 May 2023 //
REUTERS
Oculis Announces Positive Results from DIAMOND Stage 1 Phase 3 Trial
22 May 2023 //
GLOBENEWSWIRE
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
11 May 2023 //
GLOBENEWSWIRE
Oculis to Participate at Upcoming Investor Conferences
05 Apr 2023 //
GLOBENEWSWIRE
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline
04 Apr 2023 //
GLOBENEWSWIRE
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of Listing
22 Mar 2023 //
GLOBENEWSWIRE
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
16 Mar 2023 //
GLOBENEWSWIRE
Oculis Announces US Public Listing on NASDAQ
03 Mar 2023 //
GLOBENEWSWIRE
